Angiodynamics (ANGO) Enterprise Value (2010 - 2026)

Angiodynamics (ANGO) has reported Enterprise Value for 17 consecutive years, with $424.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Enterprise Value rose 17.28% year-over-year to $424.9 million; the trailing twelve-month figure through May 2026 stood at $424.9 million (up 17.28% YoY), and the FY2026 full-year result was $424.9 million, up 17.28% from the prior year.
• Enterprise Value fell to $424.9 million in Q2 2026 per ANGO's latest filing, from $439.0 million in the prior quarter.
• Across five years, Enterprise Value topped out at $897.3 million in Q1 2022 and bottomed at $143.5 million in Q1 2024.
• Historically, Enterprise Value has averaged $413.9 million across 5 years, with a median of $374.4 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Enterprise Value sank 68.82% in 2024, then surged 134.08% in 2025.
• Over 5 years, Enterprise Value stood at $481.7 million in 2022, then slumped by 58.11% to $201.8 million in 2023, then gained by 13.45% to $228.9 million in 2024, then soared by 107.02% to $473.9 million in 2025, then declined by 10.35% to $424.9 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered $424.9 million, $439.0 million, and $473.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.